NanoViricides is trading 5% higher at $1.46 in after-hours trading on November 5, 2026; no fresh company-specific announcement explaining the move was identified. - The latest identified company update, dated October 27, said its Ebola trial was progressing toward Phase IIB. - The broader market was sharply higher, which may provide context, but available evidence does not establish a direct cause. - Trading volume and activity details were unavailable, leaving the catalyst uncertain.